These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 35953760)

  • 1. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.
    Luo C; Yu T; Young KH; Yu L
    J Zhejiang Univ Sci B; 2022 Aug; 23(8):666-681. PubMed ID: 35953760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
    Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
    Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway.
    Zhang H; Chi F; Qin K; Mu X; Wang L; Yang B; Wang Y; Bai M; Li Z; Su L; Yu B
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
    Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
    Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway.
    Wu C; Chen S; Wu Z; Xue J; Zhang W; Wang S; Xindong Zhao ; Wu S
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):98. PubMed ID: 38381215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
    Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
    Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
    Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
    Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma.
    Melchor J; Garcia-Lacarte M; Grijalba SC; Arnaiz-Leché A; Pascual M; Panizo C; Blanco O; Segura V; Novo FJ; Valero JG; Pérez-Galán P; Martinez-Climent JA; Roa S
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36854569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
    Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
    Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression.
    Cao L; Chen Q; Gu H; Li Y; Cao W; Liu Y; Qu J; Hou Y; Chen J; Zhang E; He J; Cai Z
    Clin Epigenetics; 2022 Jul; 14(1):84. PubMed ID: 35799216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma.
    Kim SJ; Kim UJ; Yoo HY; Choi YJ; Kang KW
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma.
    Li L; Yang W; Pan Y; Ye R; Wang Y; Li S; Jiang H; Zhang Q; Wang X; Yan J
    Leuk Lymphoma; 2024 Jul; 65(7):895-910. PubMed ID: 38497543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.
    Mahadevan D; Morales C; Cooke LS; Manziello A; Mount DW; Persky DO; Fisher RI; Miller TP; Qi W
    PLoS One; 2014; 9(6):e95184. PubMed ID: 24893165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement.
    Liu L; Mo W; Chen M; Qu Y; Wang P; Liang Y; Yan X
    BMC Cancer; 2024 Jun; 24(1):761. PubMed ID: 38918775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
    Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of
    Ravà M; D'Andrea A; Nicoli P; Gritti I; Donati G; Doni M; Giorgio M; Olivero D; Amati B
    Sci Transl Med; 2018 Jan; 10(426):. PubMed ID: 29386360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
    Xia Y; Zhang X
    Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
    Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
    Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death.
    Liu Y; Mondello P; Erazo T; Tannan NB; Asgari Z; de Stanchina E; Nanjangud G; Seshan VE; Wang S; Wendel HG; Younes A
    Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12034-12039. PubMed ID: 30404918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
    Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
    Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.